Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. The company has been focused on the continuous evolution of its platform, the Global Library of Medicine (GLM), and strengthening its pipeline for new business and partnerships. On March 13, 2024, Treatment.com AI completed an oversubscribed non-brokered private placement of 6,295,500 special warrants and 975,000 units, issued at CA$0.40 each, raising aggregate gross proceeds of CA$2,908,200. Additionally, the company announced it is now debt-free, having settled debts totaling CA$1,111,307.40 with arm's-length creditors in two transactions completed in March and June 2024.
Dr. Essam Hamza, CEO of Treatment.com AI, expressed gratitude for the strong investor support, stating in the press release, "This is a critical inflection point for the company; the significant infusion of cash is helping expedite the tremendous commercial opportunity in front of us." The company also anticipates further financial growth with the potential exercising of warrants, which could bring in an additional CA$2 million.
In terms of partnerships, Treatment.com AI recently announced collaborations with aiXplain and Novus Health. The partnership with aiXplain aims to enhance access to Treatment.com AI's proprietary GLM by contributing to aiXplain's dynamic AI marketplace. Novus Health, a leader in health navigation, will collaborate with Treatment.com AI to develop new solutions for the health risk assessment and medical second opinion markets.
AI’s Role In Healthcare Technology
Artificial intelligence (AI) in the healthcare sector has rapidly evolved, driving significant changes in how healthcare is provided, managed, and improved. According to Healthcare-Digital on July 10, "AI is changing the way healthcare is provided, managed, and improved, in hospitals, with telehealth services, and with community healthcare." This transformation is reflected in various applications, from reducing administrative burdens to enhancing hospital communications. The sector has embraced AI-driven solutions, streamlining operations, and propelling patient care to unprecedented heights.
In the context of the broader AI market, Medcity News reported that the market is projected to grow to over US$400 billion by 2027, emphasizing the increasing demand for professionals with expertise in machine learning. The report also highlighted that within the healthcare sector, a deep knowledge of clinical sciences and healthcare skills would no longer be sufficient. "Moving ahead, healthcare corporations and academia must empower ambidextrous professionals with expertise in both machine learning and health science to stay innovative and competitive." The future of healthcare hinges on cultivating interdisciplinary leaders capable of navigating both AI and health science.
The intersection of AI and biotech has also seen substantial investments. The Healthcare Technology Report noted that industry giants like Nvidia, Google, and Microsoft have invested billions in AI to drive innovation in biotech. "Digital biology is the next frontier in technology," with Nvidia leveraging its robust GPU chips to become a central figure in the AI revolution. The synergy of generative AI and biotech has led to groundbreaking developments such as Google’s DeepMind unveiling AlphaFold, a tool for predicting protein structures with significant implications for drug discovery and crop engineering.
As AI technologies expand at an unprecedented rate, the Good Men Project underscored the urgency of exploring the uncharted frontiers of healthcare AI in a July 9 article. The potential savings and efficiencies AI can bring to healthcare are substantial. According to McKinsey & Co., there is an estimated net savings opportunity of US$14 billion to US$26 billion per year with broad applications of AI at scale in the healthcare sector.
Moreover, the integration of AI in healthcare is not without its challenges. The ethical considerations around data privacy and the need for regulatory frameworks were highlighted. As Ron Beleno, a patient advocate, stated, "In his 10 years advocating for patient rights in the health-care technology sector while juggling Alzheimer’s caregiving duties for his father, he sees health-care AI as a net benefit for patients and their families."
The advancements in AI have prompted healthcare professionals (HCPs) to focus more on AI in their studies and research. Large healthcare companies are integrating AI to drive efficiencies across different R&D and commercial processes. According to Medcity News, "Innovative clinicians of the future will prioritize gaining AI skills through study and research."
Company Catalysts
A key catalyst for Treatment.com AI is its proprietary Global Library of Medicine (GLM), an advanced AI engine designed to provide comprehensive clinical support to healthcare professionals. As noted by the company, the GLM boasts over 92% accuracy in first diagnosis, a fact underscored by a recent trial where a student using the platform achieved a 92% accuracy rate in diagnosing complex conditions under Objective Structured Clinical Examination (OSCE) conditions. This success demonstrates the platform's effectiveness in medical education and clinical support.
The company's focus on leveraging AI to address inefficiencies in the healthcare sector and its dedication to serving disenfranchised communities positions it as a forward-thinking leader in health tech. Treatment.com AI's partnerships with aiXplain and Novus Health further bolster its market presence and potential for innovation. According to Clive Maund, a technical analyst, the company's recent stock performance indicates strong growth potential. Maund noted that despite a severe decline in 2023, the stock more recently in 2024 experienced a robust recovery, suggesting major bullish implications and recommending the stock as a Buy.
As AI technologies expand at an unprecedented rate, the urgency of exploring healthcare AI's uncharted frontiers becomes more apparent. The potential savings and efficiencies AI can bring to healthcare are substantial, with McKinsey & Co. estimating a net savings opportunity of CA$14 billion to CA$26 billion per year through broad applications of AI. This highlights the significant impact and future potential of AI in transforming healthcare.
What Experts Are Saying
Technical Analyst Clive Maund provided an optimistic outlook on Treatment.com AI Inc. in his report dated July 2, 2024. Maund observed that despite a recent severe decline in the stock in 2023, Treatment.com AI experienced an extraordinarily robust recovery, bringing the stock back near recent highs. This powerful advance, he noted, has major bullish implications, suggesting that the stock may be heading higher.
Maund emphasized the immense growth potential of Treatment.com AI, particularly in addressing the inefficiencies and waste in the healthcare industry. He highlighted how AI can significantly improve the efficiency and quality of life for both healthcare professionals and patients. According to Maund, "The inefficiency and waste in the healthcare industry is legendary, with patients sitting around in waiting rooms sometimes for hours waiting to see a doctor who, due to time pressure, often cannot spend an adequate amount of time with them." He further added that doctors, nurses, and other healthcare professionals are burdened with mountains of repetitive paperwork, underscoring the potential for AI to streamline these processes.
Treatment.com AI has positioned itself as a central resource in the AI healthcare revolution. Maund pointed out that the company's Global Library of Medicine (GLM), an AI-powered online medical library, provides the highest level of qualified clinical support to healthcare professionals. This platform ensures enhanced diagnostic accuracy and transparency, which Maund believes will vastly reduce the time wasted by both doctors and patients dealing with cumbersome bureaucracy.
In his analysis, Maund referenced the company's projection that the AI healthcare market, valued at CA$11 billion in 2021, is expected to grow to CA$187 billion by 2030. He noted that the GLM, developed with input from hundreds of healthcare professionals globally, is a testament to the company's commitment to clinical quality, innovation, and efficiency in the healthcare sector. Maund also highlighted that Treatment.com's AI software recently passed a medical clinical exam with a success rate exceeding 92%, demonstrating the accuracy and reliability of their platform.
Streetwise Ownership Overview*
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS;939:FRA)
The recent stock movement, with its rapid recovery, led Maund to conclude that "something is going on," implying a positive outlook for the company's future. Based on the technical analysis, he recommended staying long on Treatment.com AI, advising that it remains a Buy, especially on any minor near-term dips, although it may not dip before continuing higher.
Ownership and Share Structure
According to SEDI.ca, insiders own 8.29%, or 3.95M common shares of Treatment.com AI. Retail investors own the remaining.
There are no institutional investors currently.
The company has 47,689,981 million outstanding shares and 36,478,895 unrestricted free-float traded shares.
As of July 11, the market cap is CA$50,551,379, and its 52-week trading range is CA$0.10 to CA$1.20 per share.
| Want to be the first to know about interesting Healthcare Services and Technology investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Treatment.com AI Inc. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
- As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc.
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
